Study guide

6.2 Endocrine and Metabolic Pharmacotherapy

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

6.2 Endocrine and Metabolic Pharmacotherapy

Key Takeaways Explain This Topic AI

Diabetes Canada guidelines recommend first-line metformin plus lifestyle, with immediate addition of SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiorenal outcome benefits for patients with ASCVD, heart failure, or CKD regardless of baseline HbA1c.

The SADMANS sick-day rule dictates holding Sulfonylureas, ACE inhibitors, Diuretics, Metformin, ARBs, NSAIDs, and SGLT2 inhibitors during acute dehydrating illness to prevent euglycemic DKA, lactic acidosis, and acute kidney injury.

Levothyroxine is taken in the morning on an empty stomach with plain water at least 30-60 minutes before breakfast, separated by >= 4 hours from calcium, iron, and antacids; serum TSH is monitored 6-8 weeks post-adjustment.

In hyperthyroidism, methimazole is preferred first-line, but propylthiouracil (PTU) is preferred in the first trimester of pregnancy; patients must report fever or sore throat immediately to evaluate for antithyroid-induced agranulocytosis.

Osteoporosis pharmacotherapy is guided by 10-year fracture risk (FRAX/CAROC); denosumab discontinuation requires bisphosphonate transition to prevent severe rebound vertebral fractures.

Last updated: August 2026

Type 2 Diabetes Mellitus: Diagnostic Criteria and Therapeutic Targets

Diabetes Canada clinical practice guidelines establish diagnostic thresholds and evidence-based management frameworks designed to optimize glycemic control while preventing microvascular and macrovascular complications.

Diagnostic Criteria for Diabetes Mellitus

Diagnosis requires one of the following laboratory criteria, confirmed with a repeat test on a separate day in the absence of unequivocal symptomatic hyperglycemia:

Fasting Plasma Glucose (FPG): ≥ 7.0 mmol/L \ge 7.0\text{ mmol/L} ≥ 7.0 mmol/L (fasting ≥ 8 hours \ge 8\text{ hours} ≥ 8 hours ).

Glycated Hemoglobin (HbA1c): ≥ 6.5 % \ge 6.5\% ≥ 6.5% (standardized, validated assay).

Two-Hour Plasma Glucose (2hPG) in 75g OGTT: ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L .

Random Plasma Glucose: ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L accompanied by classic symptoms of hyperglycemia (polyuria, polydipsia, polyphagia, unexplained weight loss).

Prediabetes: Defined by Impaired Fasting Glucose (FPG 6.1 − 6.9 mmol/L 6.1-6.9\text{ mmol/L} 6.1 − 6.9 mmol/L ), Impaired Glucose Tolerance (2hPG 7.8 − 11.0 mmol/L 7.8-11.0\text{ mmol/L} 7.8 − 11.0 mmol/L ), or HbA1c 6.0 − 6.4 % \text{HbA1c } 6.0-6.4\% HbA1c 6.0 − 6.4% .

Glycemic Targets

General Adult Target: HbA1c ≤ 7.0 % \text{HbA1c} \le 7.0\% HbA1c ≤ 7.0% (FPG / preprandial 4.0 − 7.0 mmol/L 4.0-7.0\text{ mmol/L} 4.0 − 7.0 mmol/L ; 2-hour postprandial 5.0 − 10.0 mmol/L 5.0-10.0\text{ mmol/L} 5.0 − 10.0 mmol/L ). This target balances long-term microvascular risk reduction against hypoglycemia risk.

Intensive Target: HbA1c ≤ 6.5 % \text{HbA1c} \le 6.5\% HbA1c ≤ 6.5% in younger patients with newly diagnosed diabetes, long life expectancy, and low hypoglycemia risk.

Relaxed Target: HbA1c 7.1 − 8.5 % \text{HbA1c } 7.1-8.5\% HbA1c 7.1 − 8.5% in frail elderly individuals, patients with limited life expectancy, high risk of severe hypoglycemia, or extensive comorbid conditions.

Antihyperglycemic Selection Algorithm and Cardiorenal Protection

Diabetes Canada emphasizes organ-protection-guided pharmacotherapy. When choosing antihyperglycemic agents, the presence of established atherosclerotic cardiovascular disease (ASCVD) , heart failure (HF) , or chronic kidney disease (CKD) dictates treatment selection independent of baseline HbA1c . +-------------------------------------------------------------------------+

  • | DIABETES CANADA ORGAN-PROTECTIVE SELECTION ALGORITHM |
  • +-------------------------------------------------------------------------+
  • | FOUNDATION: Metformin (titrated to 2000 mg daily) + Lifestyle |
  • | | |
  • | ASSESS CLINICAL COMORBIDITIES (REGARDLESS OF BASELINE HbA1c): |
  • | |
  • | 1. CLINICAL ASCVD (Prior MI, CAD, Stroke, PAD, Age >= 60 + Risk) |
  • | --> Add GLP-1 RECEPTOR AGONIST with proven CV benefit |
  • | (Semaglutide, Liraglutide, Dulaglutide) |
  • | OR SGLT2 INHIBITOR (Empagliflozin, Canagliflozin, Dapagliflozin)|
  • | |
  • | 2. HEART FAILURE (HFrEF or HFpEF, LVEF <= 40% or Preserved) |
  • | --> Add SGLT2 INHIBITOR (Empagliflozin, Dapagliflozin) |
  • | |
  • | 3. CHRONIC KIDNEY DISEASE (eGFR 20-60 mL/min or ACR > 3.0 mg/mmol) |
  • | --> Add SGLT2 INHIBITOR (Empagliflozin, Dapagliflozin, Canagliflozin|
  • | If SGLT2i not tolerated/contraindicated -> Add GLP-1 RA |
  • | |
  • | 4. IF GLYCEMIC TARGET NOT MET & NO HIGH-RISK CARDIORENAL COMORBIDITY: |
  • | --> Choose based on Weight Loss priority (GLP-1 RA, Tirzepatide, |
  • | SGLT2i), Hypoglycemia Avoidance (DPP-4i, GLP-1 RA, SGLT2i), |
  • | or Cost (Gliclazide, Pioglitazone, Biosimilar Insulin) |
  • +-------------------------------------------------------------------------+
  • Comprehensive Antihyperglycemic Drug Classes

Class Mechanism of Action Agents Clinical Advantages Adverse Effects & Safety Pearls

Biguanides Inhibits hepatic gluconeogenesis; enhances peripheral insulin sensitivity Metformin ( 500 − 2000 mg 500-2000\text{ mg} 500 − 2000 mg PO daily) Weight neutral; no hypoglycemia; extensive long-term safety; low cost GI distress (diarrhea, nausea); Vitamin B12 deficiency; hold if eGFR < 30 mL/min \text{eGFR} < 30\text{ mL/min} eGFR < 30 mL/min due to lactic acidosis risk

SGLT2 Inhibitors Blocks renal glucose reabsorption in proximal tubule; induces glucosuria Empagliflozin , Dapagliflozin , Canagliflozin Reduces CV death, HF hospitalizations, and CKD progression; BP and weight reduction Mycotic genital infections, UTI, volume depletion, Euglycemic DKA (monitor ketones), Fournier gangrene

GLP-1 Receptor Agonists Incretin mimetic; stimulates glucose-dependent insulin, slows gastric emptying Semaglutide (SC/PO), Liraglutide (SC), Dulaglutide (SC) Substantial weight loss; ASCVD event reduction; renal microvascular protection Nausea, vomiting, diarrhea, pancreatitis risk, gallbladder disease; contraindicated in medullary thyroid carcinoma / MEN 2

Dual GIP / GLP-1 RA Dual glucose-dependent insulinotropic polypeptide & GLP-1 agonism Tirzepatide (SC weekly) Superior HbA1c reduction and profound weight loss GI side effects (nausea, constipation); same contraindications as GLP-1 RAs

DPP-4 Inhibitors Inhibits dipeptidyl peptidase-4; prolongs endogenous GLP-1/GIP Sitagliptin , Linagliptin , Alogliptin Weight neutral; very low hypoglycemia risk; well tolerated Nasopharyngitis, joint pain, rare pancreatitis. Do not combine with GLP-1 RAs (no additive benefit)

Sulfonylureas Closes beta-cell K ATP K_{\text{ATP}} K ATP ​ channels; stimulates insulin secretion Gliclazide (MR), Glimepiride Rapid HbA1c reduction; low cost Hypoglycemia, weight gain. Gliclazide is preferred over glyburide (glyburide has active renal metabolites -> severe prolonged hypoglycemia)

Thiazolidinediones PPAR- γ \gamma γ agonist; enhances skeletal muscle and adipose insulin sensitivity Pioglitazone ( 15 − 45 mg 15-45\text{ mg} 15 − 45 mg daily) No hypoglycemia; durability of glycemic control; raises HDL Fluid retention, peripheral edema, contraindicated in Heart Failure (NYHA I-IV) ; weight gain, fracture risk in females

Acute Illness Sick-Day Management: The SADMANS Rule

During acute dehydrating illnesses (gastroenteritis, high fever, severe infections, vomiting, diarrhea), specific medications must be temporarily withheld to prevent life-threatening complications:

  • S — S ulfonylureas (hypoglycemia during reduced oral intake)
  • A — A CE Inhibitors (worsens acute renal hypoperfusion)
  • D — D iuretics / Direct Renin Inhibitors (severe volume depletion and dehydration)
  • M — M etformin (hypoperfusion and tissue hypoxia precipitate lactic acidosis)
  • A — A ngiotensin Receptor Blockers (worsens acute kidney injury)
  • N — N SAIDs (constricts afferent renal arterioles, precipitating renal failure)
  • S — S GLT2 Inhibitors (triggers Euglycemic Diabetic Ketoacidosis [euDKA] during metabolic stress/dehydration)
  • Hypoglycemia Protocol (The "Rule of 15")

Hypoglycemia is defined clinically as blood glucose < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L with or without autonomic/neuroglycopenic symptoms.

Mild-to-Moderate (Conscious, able to swallow): Ingest 15 g 15\text{ g} 15 g of simple, fast-acting carbohydrate (e.g., 4 glucose tablets, 175 mL 175\text{ mL} 175 mL [3/4 cup] of fruit juice or regular pop, 6 Life Savers, 15 mL 15\text{ mL} 15 mL [3 teaspoons] of table sugar dissolved in water).

Wait 15 Minutes: Recheck capillary blood glucose. If still < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L , treat with another 15 g 15\text{ g} 15 g of carbohydrate.

Follow-up Snack: Once glucose > 4.0 mmol/L > 4.0\text{ mmol/L} > 4.0 mmol/L , provide a complex carbohydrate and protein snack (e.g., crackers with cheese, bread with peanut butter) or regular scheduled meal to prevent recurrent hypoglycemia.

Severe Hypoglycemia (Unconscious, seizing, or requiring external assistance): Administer Glucagon ( 1 mg 1\text{ mg} 1 mg SC or IM) or Nasal Powder Glucagon ( Baqsimi 3 mg 3\text{ mg} 3 mg intranasally into one nostril). In hospital settings, administer 20 − 50 mL 20-50\text{ mL} 20 − 50 mL of IV 50 % 50\% 50% Dextrose ( D 50 W D_{50}W D 50 ​ W ) over 1-3 minutes.

  • Thyroid Disorders: Hypothyroidism and Hyperthyroidism
  • Hypothyroidism

Primary hypothyroidism is characterized by elevated serum thyroid-stimulating hormone (TSH) and low free thyroxine (free T 4 T_4 T 4 ​ ).

Pharmacological Treatment: Levothyroxine ( L -thyroxine , T 4 L\text{-thyroxine}, T_4 L -thyroxine , T 4 ​ ) is the standard of care.

Dosing Principles: Full replacement dose is approximately 1.6 μ g/kg/day 1.6\text{ }\mu\text{g/kg/day} 1.6 μ g/kg/day of ideal body weight for young, healthy adults. In elderly patients or those with known coronary artery disease, initiate at a low dose ( 25 − 50 μ g/day 25-50\text{ }\mu\text{g/day} 25 − 50 μ g/day ) and titrate slowly by 12.5 − 25 μ g 12.5-25\text{ }\mu\text{g} 12.5 − 25 μ g every 6-8 weeks to avoid precipitating myocardial ischemia or tachyarrhythmias.

Administration Instructions: Take on an empty stomach with a full glass of plain water at least 30 to 60 minutes before breakfast or at bedtime (at least 3-4 hours after the evening meal). Must be separated by at least 4 hours from calcium carbonate, iron supplements, aluminum/magnesium antacids, sucralfate, cholestyramine, and proton pump inhibitors, which significantly impair absorption.

Therapeutic Monitoring: Serum TSH is the primary monitoring parameter, assessed 6 to 8 weeks after dosage initiation or adjustment (therapeutic target 0.5 − 4.0 mIU/L 0.5-4.0\text{ mIU/L} 0.5 − 4.0 mIU/L ). In pregnancy, levothyroxine requirements increase by 30 − 50 % 30-50\% 30 − 50% ; TSH targets are tighter (trimester 1: < 2.5 mIU/L < 2.5\text{ mIU/L} < 2.5 mIU/L ; trimesters 2-3: < 3.0 mIU/L < 3.0\text{ mIU/L} < 3.0 mIU/L ).

Hyperthyroidism

Characterized by suppressed TSH ( < 0.1 mIU/L < 0.1\text{ mIU/L} < 0.1 mIU/L ) and elevated free T 4 T_4 T 4 ​ and/or free T 3 T_3 T 3 ​ , most commonly caused by Graves' disease (TSH-receptor antibodies) or toxic multinodular goiter.

Antithyroid Drugs (Thionamides):

Methimazole (MMI): Preferred first-line agent due to longer half-life (once-daily dosing), faster euthyroid attainment, and significantly lower risk of severe hepatotoxicity.

Propylthiouracil (PTU): Preferred specifically in the first trimester of pregnancy (due to methimazole-associated embryopathy: aplasia cutis, choanal atresia), in thyroid storm (because PTU inhibits peripheral conversion of T 4 T_4 T 4 ​ to T 3 T_3 T 3 ​ ), and in patients with adverse reactions to methimazole.

Black Box Warning & Critical Safety: PTU carries a high risk of severe, fulminant hepatic necrosis. Both thionamides can cause agranulocytosis ( < 0.5 % < 0.5\% < 0.5% incidence; typically within first 3 months). Patients must be educated to immediately report fever, sore throat, or signs of infection , prompt immediate drug cessation, and obtain an urgent Complete Blood Count (CBC) with differential.

Symptomatic Management: Beta-blockers without intrinsic sympathomimetic activity (e.g., propranolol 10 − 40 mg 10-40\text{ mg} 10 − 40 mg TID-QID or atenolol 25 − 50 mg 25-50\text{ mg} 25 − 50 mg daily) control adrenergic symptoms (palpitations, tremor, anxiety, heat intolerance) while awaiting thionamide efficacy.

Osteoporosis and Bone Health

Osteoporosis Canada (2023 guidelines) focuses on preventing fragility fractures using the CAROC (Canadian Association of Radiologists and Osteoporosis Canada) or FRAX tool to calculate 10-year major osteoporotic fracture risk:

Low Risk ( < 10 % < 10\% < 10% ): Lifestyle, exercise, calcium, and vitamin D.

Moderate Risk ( 10 − 20 % 10-20\% 10 − 20% ): Individualized pharmacotherapy based on patient preference and risk factors.

High Risk ( > 20 % > 20\% > 20% ), prior hip/vertebral fragility fracture, or ≥ 2 \ge 2 ≥ 2 fragility fractures: Pharmacological therapy strongly recommended.

Pharmacological Agents for Osteoporosis

Drug Class Agent & Administration Mechanism of Action Safety Pearls & Adverse Effects

Oral Bisphosphonates Alendronate ( 70 mg 70\text{ mg} 70 mg PO weekly), Risedronate ( 35 mg 35\text{ mg} 35 mg weekly or 150 mg 150\text{ mg} 150 mg monthly) Binds bone mineral hydroxyapatite; inhibits osteoclast-mediated bone resorption Take first thing in morning with plain water; stay upright for ≥ 30 min \ge 30\text{ min} ≥ 30 min ; fast ≥ 30 min \ge 30\text{ min} ≥ 30 min . Adverse effects: chemical esophagitis, atypical femur fractures (AFF), osteonecrosis of jaw (ONJ). Hold if CrCl < 30 − 35 mL/min \text{CrCl} < 30-35\text{ mL/min} CrCl < 30 − 35 mL/min

IV Bisphosphonate Zoledronic Acid ( 5 mg 5\text{ mg} 5 mg IV once yearly) Potent bisphosphonate administered over ≥ 15 min \ge 15\text{ min} ≥ 15 min Post-infusion acute phase reaction (fever, arthralgia; prevent with acetaminophen); ensure adequate hydration and normal calcium prior to infusion

RANKL Inhibitor Denosumab ( Prolia 60 mg 60\text{ mg} 60 mg SC every 6 months) Fully human monoclonal antibody that binds RANKL, blocking osteoclast formation and survival Safe in renal impairment (no dose adjustment for CKD). CRITICAL WARNING: Discontinuing denosumab causes rapid rebound bone loss and multiple vertebral fractures. Never stop without immediately transitioning to a bisphosphonate

Anabolic / Bone Forming Teriparatide (PTH 1-34, daily SC), Romosozumab (Sclerostin mAb, monthly SC) Stimulates osteoblast bone formation Reserved for very high fracture risk; romosozumab contraindicated in prior MI or stroke within 1 year

Nutritional Foundation Calcium ( 1000 − 1200 mg 1000-1200\text{ mg} 1000 − 1200 mg daily total diet + supplement), Vitamin D3 ( 800 − 2000 IU 800-2000\text{ IU} 800 − 2000 IU daily) Bone mineralization and intestinal calcium absorption Calcium carbonate requires acidic stomach (take with meals); calcium citrate can be taken without food

Obesity Pharmacotherapy

Obesity Canada guidelines recommend pharmacotherapy as an adjunct to medical nutrition therapy and physical activity for adults with BMI ≥ 30 kg/m 2 \text{BMI} \ge 30\text{ kg/m}^2 BMI ≥ 30 kg/m 2 , or BMI ≥ 27 kg/m 2 \text{BMI} \ge 27\text{ kg/m}^2 BMI ≥ 27 kg/m 2 with weight-related complications (hypertension, T2DM, dyslipidemia, OSA):

GLP-1 Receptor Agonists: Semaglutide 2.4 mg 2.4\text{ mg} 2.4 mg SC weekly ( Wegovy ) or Liraglutide 3.0 mg 3.0\text{ mg} 3.0 mg SC daily ( Saxenda ). Suppress appetite, enhance satiety, and delay gastric emptying.

Dual GIP/GLP-1 RA: Tirzepatide ( Zepbound ). Produces average weight reductions of 15 − 22 % 15-22\% 15 − 22% .

Naltrexone / Bupropion: ( Contrave 8 / 90 mg 8/90\text{ mg} 8/90 mg PO). Synergistic action on hypothalamic appetite centers and dopamine reward pathways. Contraindicated in uncontrolled hypertension, seizure disorders, chronic opioid use, or acute alcohol/benzodiazepine withdrawal.

Orlistat: ( Xenical 120 mg 120\text{ mg} 120 mg PO TID with fat-containing meals). Reversible gastric and pancreatic lipase inhibitor preventing dietary triglyceride hydrolysis. Adverse effects: fecal urgency, oily spotting, fat-soluble vitamin malabsorption (supplement vitamins A, D, E, K separated by ≥ 2 hours \ge 2\text{ hours} ≥ 2 hours ).